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The patient experience of pulmonary
hypertension: a large cross-sectional study
of UK patients
Iain Armstrong1,2*, Catherine Billings1,2, David G. Kiely1,3, Janelle Yorke4, Carl Harries5, Shaun Clayton2 and
Wendy Gin-Sing6
Abstract
Background: Pulmonary Hypertension Association UK (PHA-UK) is the only charity in the UK especially for people
affected by pulmonary hypertension (PH). To better understand the impact of PH on patients and carers beyond
clinical symptoms, the PHA-UK carried out a cross-sectional survey on the effect of PH on daily living, along with a
follow-up survey assessing the financial impact of PH.
Methods: This is a descriptive cross-sectional survey of adult patients with PH in the UK. A quantitative survey of
four key topics (time to diagnosis, quality of life [QoL], financial impact and specialist treatment), was made
available to PHA-UK members and patients on PH therapy, with a follow-up financial impact survey sent to those
responders who agreed to be contacted further. Data collection was carried out in January and February 2017 for
the main survey, and November and December 2017 for the financial impact survey.
Results: The main survey was completed by 567 individuals, and the financial follow-up survey by 171. Mean age
of responders was 69 ± 17 years with 70% female. 60% of respondents said PH had a major impact on their QoL,
with 45% reporting that treatment and management improves their QoL ‘a lot’. The time between first experiencing
symptoms and diagnosis was ≥1 year for 48% of patients, with 40% seeing 4+ doctors before diagnosis. 63% of
patients reported financial worries. Patients in part-time and full-time work reported the greatest financial burden, with
a 13 and 33% fall in monthly income respectively. Patients had positive experiences of treatment in specialist centres,
with 62% rating their care ‘excellent’, and 92% saying they preferred travelling to a specialist centre rather than seeing
a local non-specialist.
Conclusions: This study reports the largest UK survey exploring issues affecting patients with PH. The study shows that
despite the availability of new therapies, patients are still experiencing delays prior to diagnosis, and experiencing both
emotional and financial impacts from the disease. By identifying the areas patients find most important in their
treatment, this research can inform future care policies and long-term management to support patients living with PH
and their families.
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Background
Pulmonary hypertension (PH) is a pathophysiological
disorder of high blood pressure, defined by a resting
mean pulmonary artery pressure (mPAP) of ≥25mmHg,
measured through right heart catheterisation [1].
Patients with PH may experience a range of chronic
symptoms, including dyspnoea, fatigue, cough, dizziness
or syncope, chest pain, cardiac arrhythmias, oedema of
the ankles and legs, ascites, or heart failure. One form of
PH, pulmonary arterial hypertension (PAH), causes a
progressive increase in pulmonary vascular resistance,
leading ultimately to right ventricular failure and death.
Estimates from large-scale national database studies sug-
gest the global prevalence of any cause of PH is about
1% of the population, increasing to 10% in people over
65 years old [2]. In France, a national registry of 17 uni-
versity hospitals in October 2002 showed that PAH was
most likely to be detected late in the course of the dis-
ease [3]. Similarly, the REVEAL Registry (Registry to
EValuate Early And Long-term pulmonary arterial
hypertension disease management) in the USA in 2006
[4] found that over 20% of patients waited more than 2
years from the onset of symptoms attributable to PAH
and diagnosis [5]. An Australian database of adults from
four tertiary referral centres with idiopathic PAH (IPAH)
between January 2007 and December 2008 found an
even longer delay of 3.9 years [6]. Other registries used
for PH research are the Giessen PH registry in Germany
[7] and the ASPIRE (Assessing the Spectrum of Pulmon-
ary hypertension Identified at a REferral centre) registry
in the UK [8], which have both been used to explore fac-
tors linked with improved survival in patients with PH.
While large-scale database studies capture information
about medical treatment and management of the disease in
a diverse patient population, they often do not capture the
patient response to treatment, or unmet needs in the
day-to-day life of patients and their carers. In 2013, a large
international survey of 326 patients with PAH and 129
carers from five different European countries was carried
out to provide an insight into experiences of living with PH
beyond clinical symptoms [9]. The survey, consisting of
both qualitative one-to-one interviews and a quantitative
opinion-based survey questionnaire, explored four areas af-
fected by PAH (physical and practical, emotional, social and
information needs). The results showed that PAH had a
significant physical and practical impact on the daily life of
both patients and their carers, and was associated with a
significant emotional and financial burden. PAH also had a
considerable impact on patients’ intimacy, relationships,
emotional and social well-being [9]. A national survey of
114 Chinese patients with PAH using semi-structured,
face-to-face interviews revealed both physical, emotional
and financial burdens, along with social isolation caused by
a lack of public understanding of the disease [10].
Despite advances in our understanding of PH and how
it impacts patients, and despite the advent of new ther-
apies for PAH and chronic thromboembolic pulmonary
hypertension (CTEPH) [2, 3], PH remains a debilitating
illness that has a major impact on the lives of patients
and their carers. In order to improve patient care and
disease management, it is important to gain an even
greater understanding of the impact of PH and PH treat-
ment from the patient perspective, and to identify unmet
needs in the patient journey.
In the UK, patients with PAH and CTEPH (who have
the disease as a direct consequence of changes in the
pulmonary vasculature) are most commonly treated in
nine specialist centres across the country [5]. The Pul-
monary Hypertension Association UK (PHA-UK) is the
only charity in the UK that advocates exclusively for
people affected by PH. To gain information on how PH
affects daily living, PHA-UK conducted surveys in 2007,
2010 and 2017. Here we report the results of the 2017
survey along with a follow-up survey assessing the finan-
cial impact of PH. The aim was to gather updated infor-
mation on patients’ views concerning PH treatment and
management. This report should provide a vital patient
perspective for informing policy regarding the treatment
and management of individuals with PH, and to advo-
cate for the interests of people with PH in future debates
concerning policies and treatment review. The survey
provides an important platform to allow patients to
share their experiences and highlight issues that are of
most importance to them.
Methods
This was a descriptive, cross-sectional survey of adult
patients with PH in the UK. Data were collected via a
questionnaire designed to focus on the patient experi-
ence of the disease, which explored four key topics: time
to diagnosis, quality of life (QoL), financial impact and
experience of specialist treatment. A further question-
naire evaluating financial impact of PH in greater depth
was sent out to all those who had agreed to be contacted
for further surveys. Ethical approval was not requested
for the study, as no National Health Service (NHS) or
patient data were collected outside of the survey re-
sponses. A contact telephone number was provided for
patients if they had any further questions about the sur-
vey or data, and both the cover letter for the main sur-
vey and the questionnaire for the financial survey
explained that all patient information would be kept an-
onymous and confidential. Consent was implied by
virtue of completing and returning the form, and there-
fore no additional informed consent form was provided.
The questionnaire was modified from previous
PAH-UK questionnaires put together by a panel of spe-
cialist physicians and reviewed by patient representatives
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and patient advocacy groups. All questions were de-
signed to be patient-centric and focus on the everyday
experiences of patients in order to capture the issues
that were most important to the patient regarding treat-
ment and specialist care. New questions not posed in
the previous questionnaires were agreed by internal dis-
cussion between the authors, and reviewed by a patient
panel to ensure that they were relevant and sufficiently
comprehensive to capture the patient experience. The
questionnaire sent to patients was a quantitative survey
consisting of 38 separate questions grouped into five
sections; ‘before diagnosis’, ‘diagnosis’, ‘treatment’, ‘living
with pulmonary hypertension’ and ‘about you’ (see Add-
itional files 1 and 2). Other than ‘current age’ and ‘age at
diagnosis’ all questions were worded as closed questions
with discrete pre-coded response options (e.g. ‘agree/dis-
agree’ or ‘major impact/some impact/no impact’). There
was also space for patients to write in any additional
thoughts or feelings about the impact of the disease on
their life.
Data collection was carried out from January 2017 to Feb-
ruary 2017 for the main survey and November 2017 to De-
cember 2017 for the financial impact follow-up survey. The
main survey was distributed via the PHA-UK charity maga-
zine, online link and specialist centres and via the home
care delivery network. A printed hard copy of the question-
naire was sent to all members of PHA-UK, along with an
explanatory cover letter and pre-addressed envelope for
returning the questionnaire. In order to widen inclusion to
non PHA-UK members, envelopes containing the survey
and cover letter were distributed via a home care delivery
network to patients on PH-specific targeted therapy.
The follow-up financial impact questionnaire was a
quantitative survey asking 31 separate questions divided
into six sections; ‘about you’, ‘before your diagnosis’, ‘after
your diagnosis’, ‘costs related to healthcare’, ‘insurance
costs’ and ‘general costs’. Questions asking for numerical
values (quantities of money or number of healthcare
visits) were open, with a space for respondents to write
in values. All other questions were closed with discrete
pre-coded response options (see Additional files 1 and
2). Patients who completed the questionnaire were of-
fered the option of entering a draw to win £10 shopping
vouchers. The financial impact questionnaire was sent
by post to all individuals completing the main question-
naire who agreed to be contacted further. Fifteen indi-
viduals who responded to the financial impact
questionnaire were chosen at random for a qualitative
telephone interview with a PH specialist, with the inter-
view carried out with the first eight who responded. All
interviews were recorded and transcribed, and informed
consent was taken at the start of the call.
Forms completed online were inputted directly into
the analysis spreadsheet, while data from the paper
forms were checked for accurate data entry then input-
ted into the analysis spreadsheet by hand by the statisti-
cian. When all data were entered, a selection of
questionnaires were checked for accuracy against the
paper versions. Summary statistics were used to describe
individuals’ responses to the questionnaire as agreed a
priori by all authors, and the data were analysed using
IBM SPSS v22.
Results
Questionnaires were sent out to all members of the
PHA-UK via the charity magazine, specialist centres,
and online link, as well as separately via the home care
delivery network. A total of 567 individuals completed
the main survey, with 64 responses (11.3%) from the on-
line survey, and the rest from paper questionnaires. Four
of the online responses and none of the paper question-
naires were discarded prior to data entry as they were
incorrectly filled in, giving a final analysis set of 563 pa-
tients. The demographic and disease characteristics of
study participants are shown in Table 1. The financial
sub-analysis survey was sent to 351 individuals with
responses received from 171 (48.7%). For those in the fi-
nancial sub-analysis, 65% were female with a mean age
of 59.5 years, similar to those responding to the main
survey.
QoL
The results of the survey showed that 98% of patients
considered their PH to have had either a ‘major impact’
or ‘some impact’ on their overall QoL. Approximately
90% reported that PH had an impact on their mental
and emotional wellbeing and resulted in concerns about
life expectancy. Nearly 80% of patients also reported that
PH had an impact on their relationships and family
(Fig. 1a).
Table 1 Demographic and disease characteristics
All patients
(N = 563)
Age, mean [SD] 59 [17]
Female, n (%) 394 (70)
Age at diagnosis, mean [SD] 53 [19]
Currently on PH medication, n (%) 498 (88)
Comorbid conditions, n (%) 318 (56)
Congenital heart disease 91 (16)
Connective tissue disease 81 (14)
Portal hypertension 13 (2)
HIV infection 0 (0)
Sickle cell anaemia 0 (0)
Lung disease (e.g. COPD, pulmonary fibrosis) 56 (10)
COPD chronic obstructive pulmonary disease, HIV human immunodeficiency
virus, SD standard deviation
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Following treatment and management of PH, 87% of
responders reported an improvement in overall QoL,
with 45% reporting that their overall QoL improved ‘a
lot’. The majority of patients also reported at least some
improvement in their mental and emotional wellbeing
following treatment and management, which also im-
proved their concerns about life expectancy. Just under
half of patients reported that their relationships im-
proved ‘a lot’ following treatment (Fig. 1b).
When asked about their experiences of living with PH,
similar percentages of patients felt they could get sup-
port to help them cope with family life and work (76%),
to cope with their feelings (75%), and that they could
talk about their PH-related hopes and fears (76%). Add-
itional information added by patients indicated that PH
had an impact both on physical and mental aspects of
QoL, for example: “I am constantly thinking about how
it has changed my life, my health, abilities and future. I
am constantly worrying about what may or may not
happen” (female, Cleveland). However patients were also
keen to continue with their lives through treatment and
management of the disease; “PH has had a huge impact
on my life, however I am determined to minimise that
impact as much as possible” (male, Kent).
Experiences of diagnosis
. In the 12months after first noticing symptoms, 30% of
patients did not discuss these symptoms with a phys-
ician, and almost 48% had not received a diagnosis of
PH a year after first experiencing symptoms (Table 2). A
definite PH diagnosis was received by 11% of patients
who saw only one HCP, while 40% of patients saw four
or more HCPs and 9% saw seven or more HCPs prior to
receiving a diagnosis. When asked who provided the
a
b
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55
38
21
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0% 20% 40% 60% 80% 100%
Relationships and family
Concerns about life expectancy
Mental and emotional wellbeing
Overall QoL
“How big an impact does PH have on your…”
(n=567)
Major impact Some impact No impact
49
25
24
45
25
53
53
42
27
22
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13
0% 20% 40% 60% 80% 100%
Relationships
Concerns about life expectancy
Mental and emotional wellbeing
Overall QoL
“How has PH treatment and management improved your…”
(n=567)
Improved a lot Improved a little No improvement
Fig. 1 Effect of PH on QoL. (a) The impact of PH disease on QoL measures. (b) The effect of PH treatment and management on QoL measures
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diagnosis, 63% reported a PH centre consultant or nurse
specialist, and 34% a local hospital consultant. A third of
patients (33%) were admitted to hospital as an emer-
gency case due to symptoms that resulted in a PH diag-
nosis. The average time to diagnosis did not differ
between those diagnosed in 2015–2017 and those diag-
nosed pre-2015.
Patient experience of receiving their PH diagnosis
showed that the majority (57%) strongly agreed that they
understood their HCP’s explanation of what was wrong,
whilst 27% stated they had an incomplete understanding
of the disease. Responses indicated that diagnosis infor-
mation was given in a sensitive manner with 65%
strongly agreeing and only 5.3% strongly disagreeing. In
the extra information provided, several patients reported
feelings of frustration at their attempts to receive a diag-
nosis, or experiences of incorrect diagnoses: “I was get-
ting more and more breathless. I kept going to my GP
and they kept giving me asthma inhalers … It was upset-
ting and frustrating because it felt like every time I went
somewhere I was told there was nothing wrong – and
there clearly was.” (male, Barnsley); “It took me 8 years
to get a diagnosis. I was getting increasingly breathless
and I kept on going to the doctor, and kept being told it
was anxiety, or I was getting unfit.” (female,
Oxfordshire).
Financial impact
Results from the main survey showed that more than
half of the patients (63%) felt that PH had at least some
impact on their financial situation, including their ability
to attend work or education. However, for the majority
of patients, treatment and management of PH neither
improved their financial situation/financial worries
(58%) nor their ability to attend work and education
(62.7%).
Of the 171 patients in the financial sub-analysis, 35%
were in full-time employment prior to diagnosis, with
14% working part time and 30% retired. Immediately
after their diagnosis, of the patients who were working
and responded to the question (n = 93), 28% were able
to continue working as before, with another 28% giving
up work completely, 23% on long-term sick leave and
22% reducing their hours. Table 3 shows the change in
income following PH diagnosis for the 129 respondents
who provided income data, based on pre-diagnosis em-
ployment status. Overall, patients in work (either full or
part time) experienced large decreases in their monthly
salary, while those who were retired experienced a slight
increase.
Of the 104 patients who applied for benefits, less than
half (47%) were successful at the first application, while
66% reported that the department dealing with their
claim did not understand the diagnosis of PH. When
asked how easy they found applying for benefits, 7% of
the 104 patients reported it was ‘very easy’, 13% ‘quite
easy’, 25% ‘quite difficult’, 26% ‘difficult’ and 30% ‘ex-
tremely difficult’. The patient qualitative interviews re-
veal stress and worry around the process of applying for
benefits and appeals: “It’s a very daunting experience ap-
plying for benefits, it’s very complicated. The forms are
overwhelming especially when you’re ill” (female,
London); “It’s sort of like no one believes you. Like
you’re lying and it’s frustrating to get across just how
serious it is. Just because they don’t know about it
doesn’t mean it doesn’t affect you” (female, Manchester).
In the main survey, the patient qualitative responses
indicated increased costs associated with their diagnosis
related to daily living and healthcare-related travel: “My
electricity costs me more because I have my oxygen
Table 2 Time to diagnosis after experiencing symptoms
Proportion of patients, n (%)
< 3
months
3–6
months
6–12
months
1–2
years
2–3
years
3+
years
Time between noticing symptoms and going to see a doctor (n = 542) 161 (30) 128 (24) 97 (18) 68 (13) 29 (5) 59 (11)
Time between seeing general practitioner with symptoms and referral to hospital
(n = 378)
139 (37) 87 (23) 58 (15) 40 (11) 18 (5) 35 (9)
Time before referral from local hospital to specialist pulmonary hypertension
centre (n = 426a)
160 (38) 90 (21) 65 (15) 37 (9) 20 (5) 29 (7)
Time from first noticing symptoms to diagnosis with pulmonary hypertension (n =
545)
78 (14) 99 (18) 107 (20) 85 (16) 65 (12) 111
(20)
aOf these patients 25 (6%) were not referred
Table 3 Percentage change in monthly income following PH
diagnosis
Employment
status
Mean monthly income Change in
monthly
income
Pre-diagnosis Post-diagnosis
n £, mean (SD) n £, mean (SD) n % change
Full-time work 50 2081 (1607) 46 1386 (1238) 44 −33.3
Part-time work 21 1013 (683) 22 844 (525) 20 −13.4
Retired 39 1336 (878) 42 1385 (903) 39 1.5
Unable to work 14 897 (927) 14 773 (481) 13 0.0
SD standard deviation
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machine on all the time, plus a fan because the machine
heats up” (female, Gateshead); “It costs me £50 in petrol
to travel to my hospital appointments in London and
takes nearly 3 hours. If I’m kept in, it costs my husband
£55 per night to stay in hospital accommodation” (female,
Portsmouth). The financial survey asked specific questions
about additional costs related to healthcare, with patients
reporting that since diagnosis they have spent extra money
on the following: gas or electricity (53.2%), general travel
costs (43.9%), help around the house or garden (43.3%),
other household bills (28.7%) and, food costs or special
diet food (26.3%).
Treatment and specialist centres
The main survey found that patients generally had a very
positive experience of specialist PH centres (in the UK,
this is where ongoing PH treatment is prescribed and
long-term care provided). The majority of patients (89%)
stated that the support they received from care centres
was ‘excellent’ or ‘good’. A specialist PH centre was
regularly attended by 78% of respondents, with 84.6% of
those stating that they felt that they saw their specialist
often enough. More than 90% of respondents agreed
that travelling to a specialist PH centre was preferable to
being treated by non-PH specialists at a more local
hospital.
Responses to questions relating to how treatment op-
tions were handled at PH specialist centres showed that
93% of patients considered that the choice of treatments
was explained to them, 88% felt involved in the treat-
ment decision, and 84% that the side-effects of treatment
had been adequately explained to them. As well as pro-
viding information on medical treatment, the majority of
patients reported that hospital staff provided information
about support groups (68%) and the effect of PH on
work and education (59%). However, fewer (40%) stated
that hospital staff provided information about financial
support. The disease, patient age and costs were cited by
40, 25 and 16% of patients respectively as posing the
most difficulties when travelling to specialist centres.
Overall, 89.3% of patients stated that they were told
who to contact for advice on coping with symptoms of
side effects, with 78.6% given written information about
their treatment plan. A high percentage (92.6%) reported
that information regarding their disease had been given
to their general practitioner, while 63% reported that
such information had been given to their family or
carers.
Figure 2 shows what the respondents reported hoping
to gain most from their treatment. Overall, patients
prioritised QoL and increased life expectancy over redu-
cing side effects. The patient qualitative quotes often
contained praise for their treatment centres and ongoing
treatment support: “I can’t thank everyone at my
specialist centre enough for extending my life and help-
ing me to continue enjoying my retirement and family
life” (female, Hampshire); “It’s of great comfort to us to
know that, should we have a problem, we can pick up
the phone and someone will be there” (male, Newton
Stewart).
Discussion
In this study, we report on the results of the largest UK
survey exploring important issues affecting patients with
PH. The results of our survey have shown that PH im-
pacts QoL in 98% of patients. The majority of patients
experience significant delays prior to diagnosis, and this
problem has not improved over the previous decade. En-
couragingly, however, the institution of therapy results
in improvements in QoL and emotional well-being. The
experience of the UK model of highly specialised ser-
vices was overwhelmingly positive, consistent with previ-
ous smaller studies, and emphasises that patients are
willing to travel to access specialist care. Finally, this
study has quantified for the first time the very significant
impact that the diagnosis of PH makes in patients in
part-time and full-time work who, based on the data
from those patients completing our follow-up survey,
experience respective average falls in monthly income of
13 and 33% following their PH diagnosis.
Collecting patient responses, both through the survey
and the qualitative answers provided by patients, is vital
for understanding the full patient experience of the dis-
ease. PH is a long-term disease with an uncertain trajec-
tory that not only affects the individual patient, but also
their family. The PHA-UK questionnaire was designed
to be specific to the UK health and benefit systems
(where the cost of all PH medication is covered by the
National Health Service), and is therefore able to capture
the issues and worries specific to the UK PH population.
Determining which aspects of treatment and care the
patient is most concerned with can inform future care
policies and long-term treatment management to sup-
port patients and their families living with PH.
One concern highlighted was the lack of awareness of
PH among both individuals experiencing symptoms and
primary care professionals. In the PHA-UK survey al-
most half of patients did not receive a diagnosis until a
year after first experiencing symptoms, and patient com-
ments indicated that HCPs can sometimes be reluctant
to listen to patients seeking a diagnosis and even dismis-
sive of their concerns, with patients being given alterna-
tive diagnoses such as stress, anxiety, or asthma. The
percentage of patients who received a correct diagnosis
on their first approach to a HCP is low and indicative
that a greater awareness of PH and its symptoms is
needed, including the importance of shortness of breath
as a clinical sign of more serious underlying conditions.
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This is supported by results from other database and
survey studies which highlight that similar problems are
faced worldwide by patients with PH and their families
in Australia [6], France [3], and the USA [5], with delays
of several years between onset of symptoms and diagno-
sis. As well as increasing awareness among HCPs, the
PHA UK survey also indicates that increased awareness
is needed in the general population to encourage those
experiencing PH symptoms to approach their HCPs in a
timely manner, as more than 15% of patients waited over
a year before going to see a doctor with their symptoms.
As PAH is a deteriorating and life-threatening condition,
the sooner a patient can be diagnosed, the better for the
disease outcome. Further educating patients about the
process of PAH diagnosis when they first present with
symptoms may also help them to appreciate the import-
ance of reporting symptoms as soon as possible, and
help them through the diagnosis process.
While patients in the PHA-UK survey generally re-
ported that treatment and management improved their
QoL with PH, there was less of an improvement reported
in mental, emotional and relationship issues following
their treatment. Similarly, the International PAH Patient
and Carer Survey in Europe [9] reported a large emotional
burden of PAH on both patients and carers, with an im-
pact on both social and emotional wellbeing, and high
levels of mental health conditions such as anxiety and de-
pression have been reported in patients with PH [11, 12].
The emotional burden was also highlighted in the study
from China, along with concerns of isolation and loneli-
ness [10]. These non-physical issues are often difficult to
capture in database studies or clinical trials, yet they are
vitally important for fully understanding the patient
experience of the disease, and developing fully compre-
hensive care. The development of comprehensive care for
patients should include an awareness of all of these issues,
and an understanding of the emotional and informational
needs of patients.
The additional financial survey allowed a greater
exploration of the financial impact of PH. The results
are supported by similar findings from questionnaire
surveys in China [10] and Europe [9], where PH had a
high impact on the working ability and earning potential
of patients who were working (either part time or full
time) at the time of their diagnosis. It is worth remem-
bering as well, that due to the length of time between
symptoms and diagnosis, the patients were likely to have
been affected by their PH in the years before their diag-
nosis. Many patients may therefore have already experi-
enced a decrease in income, moved to part-time work,
or taken early retirement prior to the survey. The finan-
cial questionnaire did reveal less of a financial impact on
patients already in retirement, with, on average, a small
increase in income reported following PH diagnosis
most likely due to their eligibility for health-related
benefits.
The financial survey also provided an insight into the
role of the UK benefits system in providing for patients
with PH, and reveals that under the current system a
high proportion of patients are not receiving the neces-
sary support. This leads to increased financial worries
for patients, carers, and immediate family who may be
providing financial support. The qualitative interviews
carried out reveal high levels of stress and dissatisfaction
with the current benefits system, with patients finding
the application forms, assessments, repeated application
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requirements, and appeals processes a mental, emotional
and physical challenge while also dealing with the med-
ical aspects of their disease. The study also indicates a
lack of awareness of PH among individuals working
within the benefits system, leading to patients experien-
cing additional difficulties in claiming for a disease that
is both rare and an ‘invisible’ illness. Similar issues with
the financial, mental and emotional strain of the current
benefits system have been identified through qualitative
interviews of PH patients in the UK [13].
This questionnaire covers around 10% of the UK diag-
nosed population managed by the national PH network,
and is the largest survey of PH patients in the UK car-
ried out to date. Comparison of the demographics with
the UK National Audit of PH Services indicates that it
covers a representative sample of PH patients in the UK
[14]. Limitations of this study are typical for this form of
questionnaire-based research. In particular the sample is
self-selecting for those patients willing to answer and
send back the questionnaire. This is also true of the fi-
nancial survey, where around half of those who agreed
to be contacted further returned the questionnaire, al-
though it is difficult to speculate how this self-selection
may have affected the data. As this is a descriptive study,
no further statistical analysis was carried out on associa-
tions between the data.
These data are supported by findings from other data-
base studies and questionnaire surveys, and show the
importance of considering the financial and emotional
aspects of patient care, alongside medical treatment and
management. They also indicate that the length of time
between the first appearance of symptoms and diagnosis,
due to a lack of awareness among patients and first-line
HCPs, is unacceptably long in the case of this deteriorat-
ing condition. Reducing the financial hardship incurred
by living with PH would also reduce the stress and emo-
tional burden of the disease. While in the UK the cost of
medication is covered by the NHS, there is still a need
to increase awareness of the disease in agencies respon-
sible for supplying benefits or financial support to indi-
viduals with PH. By engaging with patient experiences, a
full understanding of the patient journey can be put to-
gether and used for public healthcare advocacy, ensuring
patient needs are reflected in treatment guidelines and
legislation to improve health, wellbeing and QoL of pa-
tients with PH.
Conclusions
This study reports on the largest UK-wide survey explor-
ing the key issues affecting patients with PH. The study
shows that the time between first experiencing symp-
toms and final diagnosis is still too long in the case of
this deteriorating condition, and that, despite the avail-
ability of new therapies, patients are experiencing both
emotional and financial impacts from the disease. The
study identifies the areas patients find most important in
their treatment, which is important for informing future
care policies and long-term management to support pa-
tients living with PH and their families.
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